Pembrolizumab Induces Significantly Improved PFS in MSI-H/dMMR Colorectal Cancer

The trial evaluating the first-line treatment of pembrolizumab in patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer demonstrated improved PFS compared with chemotherapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news